Description
An antibiotic; inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively); induces cell cycle arrest in the G2/M phase in human leukemia K562 cells (MED = 30 ng/ml); is cytotoxic to doxorubicin-resistant and -susceptible P388 mouse leukemia cells (IC50s = 27 and 45 nM, respectively); inhibits growth of the mycelial, but not yeast form of C. albicans, C. krusei, C. tropicalis, and C. lusitaniae (MICs = 3.1-25 μg/ml)
Formal name: (9S,10R,11R,13R)-10,11,12,13-tetrahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonine-1,3(2H)-dione
Synonyms: BMY 41950|RK-1409
Molecular weight: 480.5
CAS: 125035-83-8
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Antifungals||Product Type|Biochemicals|Kinase Inhibitors|CaMKs||Product Type|Biochemicals|Kinase Inhibitors|PKA||Product Type|Biochemicals|Kinase Inhibitors|PKC||Product Type|Biochemicals|Natural Products|Microbial Metabolites||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Death||Research Area|Cancer|Cell Signaling|cAMP Signaling||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling||Research Area|Cancer|Multidrug Resistance||Research Area|Cell Biology|Cell Signaling|cAMP Signaling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Fungal Diseases|Candidiasis
